Kirk E Evoy1, Jordan R Covvey2, Alyssa M Peckham3, Leslie Ochs4, Kyle E Hultgren5. 1. University of Texas at Austin College of Pharmacy, 7703 Floyd Curl Drive - MC 6220, San Antonio, TX, 78229, USA; University Health System, 1055 Ada St., San Antonio, TX, 78223, USA. Electronic address: evoy@uthscsa.edu. 2. Duquesne University School of Pharmacy, 600 Forbes Avenue, Pittsburgh, PA, 15282, USA. Electronic address: covveyj@duq.edu. 3. Northeastern University School of Pharmacy, 360 Huntington Ave., Boston, MA 02115, USA; Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114, USA. Electronic address: a.peckham@northeastern.edu. 4. University of New England College of Pharmacy, 716 Stevens Avenue, Portland, ME, 04103, USA. Electronic address: lochs1@une.edu. 5. Purdue University College of Pharmacy, 575 Stadium Mall Drive, West Lafayette, IN, 47907, USA; Purdue University College of Pharmacy Center for Medication Safety Advancement, 8626 E 116(th) St., Suite 200, Fishers, IN, 46038, USA. Electronic address: khultgre@purdue.edu.
Abstract
BACKGROUND: Reports of gabapentinoid (gabapentin and pregabalin) misuse have increased in recent years. Pharmacovigilance data from the Food and Drug Administration Adverse Event Reporting System (FAERS) provides a useful examination of adverse drug event (ADE) reporting for safety signal detection. OBJECTIVE: This study was conducted to analyze epidemiological information on the nature and extent of gabapentin/pregabalin abuse utilizing the FAERS database. METHODS: A query was designed utilizing SafeRx, an indexed, searchable database of FAERS data from October 2012-December 2016. All-cause and abuse-related (including abuse/misuse/dependence/overdose events) ADE reports for gabapentin and pregabalin were isolated, as well as limited demographic data. The proportional reporting ratio (PRR) was calculated to compare signal detection. RESULTS: A total of 10,038 all-cause ADEs were reported to FAERS for gabapentin, including 576 (5.7%) abuse-related events. For pregabalin, 571 all-cause ADEs were identified, including 58 (10.2%) related to abuse. Compared to all-cause ADEs, those involved in abuse-related events were younger and more likely to be male. The PRR of pregabalin versus gabapentin abuse-related events was 1.77. CONCLUSION: Though not traditionally thought of as drugs of abuse, over 600 cases of gabapentinoid abuse were reported in the time frame analyzed, prompting the need for further study and regulatory investigation.
BACKGROUND: Reports of gabapentinoid (gabapentin and pregabalin) misuse have increased in recent years. Pharmacovigilance data from the Food and Drug Administration Adverse Event Reporting System (FAERS) provides a useful examination of adverse drug event (ADE) reporting for safety signal detection. OBJECTIVE: This study was conducted to analyze epidemiological information on the nature and extent of gabapentin/pregabalin abuse utilizing the FAERS database. METHODS: A query was designed utilizing SafeRx, an indexed, searchable database of FAERS data from October 2012-December 2016. All-cause and abuse-related (including abuse/misuse/dependence/overdose events) ADE reports for gabapentin and pregabalin were isolated, as well as limited demographic data. The proportional reporting ratio (PRR) was calculated to compare signal detection. RESULTS: A total of 10,038 all-cause ADEs were reported to FAERS for gabapentin, including 576 (5.7%) abuse-related events. For pregabalin, 571 all-cause ADEs were identified, including 58 (10.2%) related to abuse. Compared to all-cause ADEs, those involved in abuse-related events were younger and more likely to be male. The PRR of pregabalin versus gabapentin abuse-related events was 1.77. CONCLUSION: Though not traditionally thought of as drugs of abuse, over 600 cases of gabapentinoid abuse were reported in the time frame analyzed, prompting the need for further study and regulatory investigation.
Authors: Elizabeth A Ibiloye; Jamie C Barner; Kenneth A Lawson; Karen L Rascati; Kirk E Evoy; Alyssa M Peckham Journal: Clin Drug Investig Date: 2021-02-12 Impact factor: 2.859
Authors: Eladio Fernández-Liz; Maria Estrella Barceló-Colomer; Laura Gómez-Ganda; Carlota Varon-Galcera; Pilar Lalueza-Broto; Francisco Javier Medel-Rebollo; Maria Angeles Hortelano-García; Elisabeth Martín-Gracia Journal: Clin Drug Investig Date: 2022-04-21 Impact factor: 2.859
Authors: Kirk E Evoy; Sarvnaz Sadrameli; Jillian Contreras; Jordan R Covvey; Alyssa M Peckham; Megan D Morrison Journal: Drugs Date: 2021-01 Impact factor: 9.546